On May 21, 2020, Austrianova (http://www.austrianova.com) and Cells for Cells (http://www.c4c.cl/) announced that the companies, and their academic partners, have just jointly published a ground-breaking, peer-reviewed, scientific publication on a novel, cost- and time-saving method to generate extracellular vesicles (EVs) from encapsulated mesenchymal stem cells (MSCs). These EVs are known to mediate many of the therapeutic effects of stem cells. The authors show that Austrianova’s proprietary Cell-in-a-Box® encapsulation technology can be used to produce and deliver EVs from encapsulated MSCs, as demonstrated using Cells for Cells’ proprietary MSCs. The article, which was co-authored with academic partners at the University of the Andes, Chile, and the University of Veterinary Medicine, Vienna, Austria, was published online on May 21, 2020 in Frontiers in Pharmacology (https://www.frontiersin.org/articles/10.3389/fphar.2020.00679/full). The open-access article is titled “Semipermeable Cellulose Beads Allow Selective and Continuous Release of Small Extracellular Vesicles (sEV) from Encapsulated Cells.” Currently, EVs have to be purified from cell culture conditioned media using tedious, costly, and time-consuming protocols that are difficult to perform under Good Manufacturing Practices (GMP) conditions. The Cell-in-a-Box® encapsulation technology allows efficient enrichment of EVs at high concentration because they are released from the encapsulated cells via the semipermeable pores, which selectively enable the release of small particles, but not of the MSCs. Moreover, Cell-in-a-Box® provides 3D culture conditions for the MSCs.Login Or Register To Read Full Story